Is genetic screening necessary for determining the possibility of venous thromboembolism in cancer patients?

Medical principles and practice : international journal of the Kuwait University, Health Science Centre Pub Date : 2012-01-01 Epub Date: 2011-11-05 DOI:10.1159/000333394

Ece Onur, Adnan Taner Kurdal, Berrin Tugrul, Ihsan Iskesen, Pınar Dundar, Fatma Taneli, Cevval Ulman, Ahmet Var

{"title":"Is genetic screening necessary for determining the possibility of venous thromboembolism in cancer patients?","authors":"Ece Onur, Adnan Taner Kurdal, Berrin Tugrul, Ihsan Iskesen, Pınar Dundar, Fatma Taneli, Cevval Ulman, Ahmet Var","doi":"10.1159/000333394","DOIUrl":null,"url":null,"abstract":"Objective: To determine the risk of an association with some genetic polymorphisms involved in venous thromboembolism (VTE) gene variations (FVL, FV H1299R, FII G20210A, MTHFR C677T, MTHFR A1298C, PAI-1 4G/5G, β-ﬁbrinogen -455 G → A, FXIII Val34Leu and GpIIIa HPA-1a) in cancer patients.Subjects and methods: Among 78 cancer patients, 28 who had proven first episode of VTE were selected as the patient group, with 50 control samples selected from age-, sex- and body mass index-matched healthy volunteers (healthy group). The differences in frequency of genetic polymorphisms were found to be statistically insignificant between these two groups.Results: Logistic regression analysis after adjustment for age, sex, smoking and hypertension showed no difference. The screened mutations of these genes were not significantly associated with VTE risk.Conclusion: There is no possible benefit from genetic screening tests regarding VTE in cancer patients.","PeriodicalId":520708,"journal":{"name":"Medical principles and practice : international journal of the Kuwait University, Health Science Centre","volume":" ","pages":"160-3"},"PeriodicalIF":0.0000,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000333394","citationCount":"16","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical principles and practice : international journal of the Kuwait University, Health Science Centre","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000333394","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2011/11/5 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 16

Abstract

Objective: To determine the risk of an association with some genetic polymorphisms involved in venous thromboembolism (VTE) gene variations (FVL, FV H1299R, FII G20210A, MTHFR C677T, MTHFR A1298C, PAI-1 4G/5G, β-ﬁbrinogen -455 G → A, FXIII Val34Leu and GpIIIa HPA-1a) in cancer patients.

Subjects and methods: Among 78 cancer patients, 28 who had proven first episode of VTE were selected as the patient group, with 50 control samples selected from age-, sex- and body mass index-matched healthy volunteers (healthy group). The differences in frequency of genetic polymorphisms were found to be statistically insignificant between these two groups.

Results: Logistic regression analysis after adjustment for age, sex, smoking and hypertension showed no difference. The screened mutations of these genes were not significantly associated with VTE risk.

Conclusion: There is no possible benefit from genetic screening tests regarding VTE in cancer patients.

查看原文本刊更多论文

基因筛查对于确定癌症患者静脉血栓栓塞的可能性有必要吗?

目的:探讨与癌症患者静脉血栓栓塞(VTE)基因变异(FVL、FV H1299R、FII G20210A、MTHFR C677T、MTHFR A1298C、PAI-1 4G/5G、β-纤维蛋白原-455 G→A、FXIII Val34Leu和GpIIIa HPA-1a)相关的遗传多态性的风险。研究对象和方法:78例癌症患者中，经证实首次发生静脉血栓栓塞的患者28例为患者组，年龄、性别、体重指数相匹配的健康志愿者50例作为对照(健康组)。两组间基因多态性频率差异无统计学意义。结果:调整年龄、性别、吸烟、高血压等因素后进行Logistic回归分析，差异无统计学意义。筛选的这些基因突变与静脉血栓栓塞风险无显著相关性。结论:癌症患者静脉血栓栓塞的基因筛查试验没有可能带来益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical principles and practice : international journal of the Kuwait University, Health Science Centre

自引率

0.00%

发文量